APTO (Aptose Biosciences) LT-Debt-to-Total-Asset : 1.01 (As of Dec. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Aptose Biosciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aptose Biosciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 1.01.

Aptose Biosciences's long-term debt to total assets ratio increased from Dec. 2023 (0.05) to Dec. 2024 (1.01). It may suggest that Aptose Biosciences is progressively becoming more dependent on debt to grow their business.

Aptose Biosciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Aptose Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences LT-Debt-to-Total-Asset Chart

Aptose Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.05

1.01

Aptose Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.04	0.04	0.94	1.01

Aptose Biosciences LT-Debt-to-Total-Asset Calculation

Aptose Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	10.211	/	10.127
	=

Aptose Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	10.211	/	10.127
	=

Aptose Biosciences (NAS:APTO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aptose Biosciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptose Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (NAS:APTO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

LTI0:Germany LTI0:Germany APS:Canada

Address

251 Consumers Road, Suite 1105, Toronto, ON, CAN, M2J 4R3

Website

https://www.aptose.com

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Executives

William G. Rice	director, officer: Chair, President & CEO	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Bernd R. Seizinger	director	535 BOYLSTON STREET, BOSTON MA 02116
Fletcher Payne	officer: SR VP & Chief Fin. Officer	260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Philippe Ledru	officer: Chief Commercial Officer	C/O APTOSE BIOSCIENCES INC., 2511 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Denis R Burger	director	CYTODYN INC., 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Erich Platzer	director
Rafael Bejar	officer: Chief Medical Officer	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Wilson Donald R. Jr.	10 percent owner	540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Holdings, Llc	10 percent owner	540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Commodities, Llc	10 percent owner	540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Warren Whitehead	director	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Gregory K. Chow	officer: Senior VP & CFO	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Jotin Marango	officer: Senior VP, Chief Bus. Officer	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Caroline M Loewy	director	300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Mark D. Vincent	director	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3